Results 11 to 20 of about 19,002 (159)

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors [PDF]

Cancer Medicine
Background Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1.
Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing   +12 more
doaj   +4 more sources

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept [PDF]

Indian Journal of Ophthalmology
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir, Mahdi Hassoun, Rola N Hamam, Ziad Fayez Bashshur   +3 more
doaj   +3 more sources

Ziv-aflibercept in macular disease. [PDF]

Br J Ophthalmol, 2015
Aflibercept is an approved therapy for neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept.
Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME.   +3 more
europepmc   +6 more sources

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding [PDF]

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +3 more sources

Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study [PDF]

Clinical Ophthalmology, 2018
Juliane Maria Doepfner,1 Stephan Michels,1,2 Nicole Graf,3 Matthias Dieter Becker,1 Florentina Joyce Freiberg1 1Department of Ophthalmology, Triemli City Hospital, Zurich, Switzerland; 2Faculty of Medicine, University of Zurich, Zurich, Switzerland ...
Doepfner JM, Michels S, Graf N, Becker MD, Freiberg FJ   +4 more
doaj   +3 more sources

Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation. [PDF]

Sci Rep, 2020
AbstractAflibercept (AFL) is an Fc fusion protein used in the treatment of colorectal cancers and different ophthalmological diseases. There are two medicines in which AFL is the active substance: Zaltrap and Eylea, referred as ziv-AFL and AFL respectively. No proper accelerated degradation studies were published on either AFL or ziv-AFL. These studies
Hermosilla J, Pérez-Robles R, Salmerón-García A, Casares S, Cabeza J, Bones J, Navas N.   +6 more
europepmc   +9 more sources

A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. [PDF]

Oncologist, 2018
Abstract Lessons Learned The combination of the antiangiogenic agent ziv-aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested.
Meehan R, Kummar S, Do K, O'Sullivan Coyne G, Juwara L, Zlott J, Rubinstein L, Doroshow JH, Chen AP.   +8 more
europepmc   +5 more sources

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection [PDF]

BMC Ophthalmology, 2022
Background Diabetic macular edema (DME) is a leading cause of visual loss in diabetic patients and is managed using multiple anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab and aflibercept.
Amin E. Nawar, Tamer Wasfy, Heba M. Shafik   +2 more
doaj   +2 more sources

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane [PDF]

Case Reports in Ophthalmological Medicine, 2017
Purpose. To study the effect and outcome of intravitreal Ziv-Aflibercept (IVZ) in treatment of Chronic Central Serous Chorioretinopathy (CSCR) related Choroidal Neovascular Membrane (CNVM). Methods.
Nishant Radke, Charudutt Kalamkar, Amrita Mukherjee, Snehal Radke   +3 more
doaj   +3 more sources

Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. [PDF]

Eye (Lond), 2022
To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME).A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis between 2016 and 2018 who had a minimum follow-up of 6 months was retrieved and ...
Braimah IZ, Amoaku WM.
europepmc   +3 more sources